BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1541282)

  • 1. Kinetic parameters for the uptake of anthracycline by drug-resistant and drug-sensitive K562 cells.
    Tarasiuk J; Garnier-Suillerot A
    Eur J Biochem; 1992 Mar; 204(2):693-8. PubMed ID: 1541282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells.
    Frezard F; Garnier-Suillerot A
    Eur J Biochem; 1991 Mar; 196(2):483-91. PubMed ID: 1672520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamics of the anthracycline-nuclei interactions in drug-resistant and drug-sensitive K562 cells.
    Tarasiuk J; Garnier-Suillerot A
    Biochem Pharmacol; 1992 Jun; 43(12):2575-80. PubMed ID: 1632816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells.
    Pereira E; Borrel MN; Fiallo M; Garnier-Suillerot A
    Biochim Biophys Acta; 1994 Jan; 1225(2):209-16. PubMed ID: 7904185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei.
    Frezard F; Garnier-Suillerot A
    Biochim Biophys Acta; 1990 Nov; 1036(2):121-7. PubMed ID: 2223830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells.
    Tarasiuk J; Foucrier J; Garnier-Suillerot A
    Biochem Pharmacol; 1993 May; 45(9):1801-8. PubMed ID: 8098603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.
    Kunimoto S; Miura K; Umezawa K; Xu CZ; Masuda T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1984 Dec; 37(12):1697-702. PubMed ID: 6526737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS; Myers MT; Sartorelli AC
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhodamine 123: is it an appropriate dye to study P-glycoprotein activity in adriamycin-resistant K562 cells?
    Denis-Gay M; Petit JM; Ratinaud MH
    Anticancer Res; 1995; 15(1):121-6. PubMed ID: 7733620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of the interaction of superoxide ion and ascorbate with anthracycline antibiotics.
    Afanas'ev IB; Polozova NI; Kuprianova NS; Gunar VI
    Free Radic Res Commun; 1987; 3(1-5):141-50. PubMed ID: 2854525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells.
    Borrel MN; Pereira E; Fiallo M; Garnier-Suillerot A
    Eur J Biochem; 1994 Jul; 223(1):125-33. PubMed ID: 7518390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of iron-anthracycline complexes with living cells: a microspectrofluorometric study.
    Fiallo M; Laigle A; Garnier-Suillerot A; Amirand C; Ballini JP; Chinsky L; Duquesne M; Jolles B; Sureau F; Turpin PY
    Biochim Biophys Acta; 1993 Jun; 1177(3):236-44. PubMed ID: 8323977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
    Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
    J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
    Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
    Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
    Slapak CA; Daniel JC; Levy SB
    Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K; Kunimoto S; Takeuchi T
    Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells.
    Schaefer A; Dahle M; Radenz G; Steinheider G; Marquardt H
    Leukemia; 1991 Feb; 5(2):95-100. PubMed ID: 2020200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
    Coley HM; Twentyman PR; Workman P
    Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
    Tapiero H; Fourcade A; Vaigot P; Farhi JJ
    Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.